Group 6A: HER2+ Pan-Cancers; Clinical Trials; Novel Targets & Therapies

Poster #TPS1114: A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors

Poster #3087: CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors